Thailand tightens cannabis rule after tourists caught trying to smuggle drug out
Dispensaries will be allowed to sell cannabis only to those with licenses or with prescriptions from medical professionals, including traditional medicine practitioners, when proposed changes to existing rules take effect in about 40 days.
The amount sold will also be limited to 30 days of use, according to the Ministry of Public Health.
The new rules, which will be binding on locals and foreigners alike, come after Thai authorities intercepted 73kg (160lbs) of cannabis earlier this week at Bangkok's Suvarnabhumi airport.
Weed smuggled out of Thailand has reached the United Kingdom, India, Pakistan, Hong Kong and many other destinations, Public Health Minister Somsak Thepsuthin said. Thailand will now make it harder to access cannabis except for medical reasons, he added.
Thailand was the first country in Asia to decriminalise cannabis in 2022, but has so far struggled to regulate and contain its free use.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
2 hours ago
- South China Morning Post
EdUHK Prof Mette Hjort Champions Cultures of Care for a Flourishing Hong Kong
[The content of this article has been produced by our advertising partner.] In a flourishing community, care should extend beyond interpersonal relationships, manifesting across various societal domains including film, healthcare, culture, and education. As an expert in cultures of care, Prof Mette Hjort, Chair Professor of Film and Media Studies of the Faculty of Humanities (FHM) at The Education University of Hong Kong (EdUHK), challenges prevailing norms that often prioritise productivity and commercial outcomes. Through her groundbreaking research on cultures of care, Prof Hjort explores how care can be thoughtfully integrated into motion pictures, healthcare, culture, and education to foster a more caring Hong Kong, generating ethical, cultural, social, environmental, and health benefits. As Hong Kong increasingly embraces care-centred approaches across various sectors, Prof Hjort's research aims to contribute meaningfully to a more flourishing society where care becomes a fundamental value, rather than an afterthought. Current Landscape: Public Discourse on Cultures of Care Hjort notes that conversations around cultures of care in Hong Kong are steadily gaining momentum, with pioneering organisations in the creative arts sector leading the way. "The public discourse on this topic is increasingly robust in the city," she observes, highlighting Tai Kwun's significant community engagement initiatives—particularly their 2025 project With a Song in My Heart. The project thoughtfully unites musicians, cancer patients, survivors, and caregivers through expressive jazz performances to share their challenges and experiences on the journey of battling cancer. "While Hong Kong acknowledges the value of creative arts for wellbeing, we haven't yet developed a comprehensive public understanding that cultural interventions can sometimes serve people's needs more effectively than pharmacological approaches," she reflects. "The recognition of culture's healing potential is growing, but considerable work remains to fully integrate this understanding into our healthcare approaches and public consciousness."
South China Morning Post
3 hours ago
- South China Morning Post
Innogen's shares almost quadruple in Hong Kong trading debut amid pharmaceutical bull run
Shares of Guangzhou Innogen Pharmaceutical Group soared on their Hong Kong debut, buoyed by strong investor appetite for China's pharmaceuticals sector, which has enjoyed rising valuations and solid performance. Trading under the stock code 2591, Innogen's shares first changed hands at HK$72 on Friday, almost four times more than the initial public offering (IPO) price of HK$18.68 despite a declining market. The city's benchmark Hang Seng index opened almost 1 per cent lower. The debut performance of the maker of drugs for diabetes and other metabolic diseases followed Chinese vaccine maker Ab&B Bio-Tech's 158 per cent gain on its first day of trading on Monday. The success of Innogen's share sale was bolstered by a rally in major biotech companies in Hong Kong, which gained an average of 137 per cent this year, according to a CCB International report on Wednesday. Investors were willing to pay more for each unit of sales in the sector as the price-to-sales ratio rose to 18.8 times from 8.7 times in December 2024. Innogen, which raised HK$683 million (US$87.2 million) through its IPO, followed peers that also took advantage of the Hong Kong exchange's Chapter 18A listing rule for pre-revenue biotech firms. These included Nanjing Leads Biolabs and TransThera Sciences, whose shares have jumped 88.3 per cent and 263.5 per cent, respectively, since their debuts this year. Innogen also emerged as one of the most popular IPOs among retail investors, as many were unable to successfully subscribe to the stock during the IPO stage, boosting sentiment for its debut.
South China Morning Post
11 hours ago
- South China Morning Post
Harmful substances found in 13 out of 28 school shoe models sold in Hong Kong
Nearly half of 28 models of primary school shoes sold in Hong Kong contain harmful substances, with carcinogens exceeding international safety limits found in four, tests by the consumer watchdog have revealed. The Consumer Council on Thursday also published international test results showing that three out of 22 child car seats models sold locally had 'weaker crash protection', and trace amounts of harmful substances were found in eight. For the shoe results, published ahead of the start of the new school year, the council tested the 28 models for chemical safety and physical performance. The shoes cost from HK$198 to HK$599. It found 'various harmful substances' in 13 of them, including the carcinogen chromium VI, aromatic amines, formaldehyde and the reproductive toxicant phthalates. Chromium VI is typically formed during leather tanning and can cause lung cancer. The International Agency for Research on Cancer (IARC) has classified it as a Group 1 'carcinogenic to humans' agent.
